Crizanlizumab - Novartis
Alternative Names: Adakveo; Crizanlizumab-tmca - Novartis; Ryverna; SEG-101; Sel G1Latest Information Update: 20 Feb 2025
At a glance
- Originator Selexys Pharmaceuticals
- Developer Novartis
- Class Antivirals; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action P selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Vaso-occlusive crisis
- Phase II Priapism; Vascular disorders
- Phase I/II Myelofibrosis
Most Recent Events
- 07 Dec 2024 Updated efficacy and adverse event data from the phase II SOLACE-KIDS trial in Sickle cell disease presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 24 Oct 2024 Novartis initiates phase III SPARKLE trial for Vaso-occlusive-crisis (In adolescent, In adult, In the elderly) (IV, Infusion) in USA (NCT06439082)
- 03 Jun 2024 Novartis Pharmaceuticals plans a phase III SPARKLE trial for Vaso-occlusive-crisis (In adolescent, In adult, In the elderly) (IV, Infusion) in October 2024 (NCT06439082)